Ghaeli Padideh, Vejdani Shaghayegh, Ariamanesh Atefeh, Hajhossein Talasaz Azita
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ; Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2015 Summer;14(3):851-5.
Several studies have reported that the antioxidant properties of melatonin can provide cardiac protection through scavenging of free radicals. This study sought to investigate the efficacy of melatonin on cardiac biomarkers, myocardial-specific protein high sensitive troponin-T (hs-TnT) and creatine kinase-MB (CK-MB), in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). In this randomized clinical trial, a total of 40 patients with STEMI planned to undergo pPCI were randomly assigned to two groups of receiving melatonin plus standard treatment [n=20] and control group, receiving only standard therapy [n=20]. The following parameters including hsTnT and CK-MB were assessed preoperatively (baseline) and at 6 hours after procedure. Melatonin could significantly reduce the level of CK-MB (118.2 ± 21.09 IU/L in the treated group versus 198.24 ± 20.94 IU/L in the control group; p-value = 0.01). However, there was no difference in the mean hs-TnT level between two groups (2491 ± 664 μg/L vs. 2801 ± 620 μg/L; p value = 0.73). Our results revealed that melatonin can be considered as a safe adjunctive medication to the standard regimen after pPCI for the aim of decreasing cardiovascular events. Meanwhile, this was a pilot study with a small number of patients and further studies are needed to confirm the beneficial effect of melatonin in patients with STEMI.
多项研究报告称，褪黑素的抗氧化特性可通过清除自由基来提供心脏保护作用。本研究旨在调查褪黑素对接受直接经皮冠状动脉介入治疗（pPCI）的ST段抬高型心肌梗死（STEMI）患者心脏生物标志物、心肌特异性蛋白高敏肌钙蛋白T（hs-TnT）和肌酸激酶同工酶MB（CK-MB）的疗效。在这项随机临床试验中，共有40例计划接受pPCI的STEMI患者被随机分为两组，一组接受褪黑素加标准治疗[n = 20]，另一组为对照组，仅接受标准治疗[n = 20]。在术前（基线）和术后6小时评估以下参数，包括hsTnT和CK-MB。褪黑素可显著降低CK-MB水平（治疗组为118.2±21.09 IU/L，对照组为198.24±20.94 IU/L；p值 = 0.01）。然而，两组之间的平均hs-TnT水平没有差异（2491±664 μg/L对2801±620 μg/L；p值 = 0.73）。我们的结果表明，为了减少心血管事件，褪黑素可被视为pPCI术后标准治疗方案的一种安全辅助药物。同时，这是一项样本量较小的初步研究，需要进一步研究来证实褪黑素对STEMI患者的有益作用。
